A PYMNTS Company

Ireland/US: Actavis beats Valeant for Botox maker

By  |  November 17, 2014

Ireland-based Actavis has emerged victorious from a bidding to acquire US-based Botox maker Allergan, according to reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Actavis will purchase Allergan for $66 billion, beating out Canada’s Valeant for the deal. Valeant had proposed an unsolicited bid for the assets of $50 billion.

    In a statement following news of Actavis’s deal, Valeant Chairman and CEO J. Michael Pearson said he could not justify paying such a high price for Allergan.

    Allergan had fought to avoid a hostile takeover for the last six months, say reports. The combined company will have revenue of $23 billion.

    Full content: CNBC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.